

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

FIGURE 1



PATENT PENDING
JUN 25 2002
U.S. PATENT AND TRADEMARK OFFICE

FIGURE 2

Mean plasma concentration-time profiles of metformin in twelve subjects after an oral administration of metformin XT (4 x 500 mg q.d., lot No. P98231) or GLUCOPHAGE (2 x 500 mg b.i.d.)




FIGURE 3

Mean plasma concentration-time profiles of metformin in eight healthy subjects after multiple oral doses of metformin XT (4×500 mg q.d.)




FIGURE 4




FIGURE 5.

Mean plasma glucose concentration-time profiles after 4 weeks of treatment with metformin XT (2 x 1000 q.d. with dinner) or GLUCOPHAGE (1 x 1000 mg b.i.d.)




Fig 6

Metformin HCl Dissolution Profiles

Paddle at 75rpm, in pH7.5




Fig 7

Metformin HCl Dissolution Profiles

Paddle at 75rpm, in pH7.5




Fig 8

Metformin HCl Dissolution Profiles
Paddle at 75rpm in pH7.5

